{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:07:38Z","timestamp":1792868858059,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaccao.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T01:46:38Z","timestamp":1752630398000},"page":"538-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6380","authenticated-orcid":false,"given":"Orly","family":"Leiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-9888","authenticated-orcid":false,"given":"Anthony","family":"Kanelidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Swat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Gozdecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Grinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"DeCara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-7454","authenticated-orcid":false,"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvarez-Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2025.05.010_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2025.05.010_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jaccao.2025.05.010_bib3","first-page":"895","article-title":"Myeloproliferative neoplasms","volume":"377","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jaccao.2025.05.010_bib5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaccao.2025.05.010_bib6","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib7","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2025.05.010_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib11","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s11864-024-01255-8","article-title":"Myeloproliferative neoplasms and cardiovascular disease: a review","volume":"25","author":"Leiva","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.05.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100051","article-title":"Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes","volume":"2","author":"How","year":"2025","journal-title":"Blood Vessels Thromb Hemost"},{"key":"10.1016\/j.jaccao.2025.05.010_bib15","article-title":"In-hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: insights from the National Readmissions Database","volume":"49","author":"Leiva","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jaccao.2025.05.010_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.202306-1001ED","article-title":"Pulmonary hypertension in myeloproliferative neoplasms: new insights and unexplored horizons","volume":"208","author":"Leiva","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","article-title":"Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease","volume":"117","author":"Leiva","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib18","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","article-title":"Incremental utility of right ventricular dysfunction in patients with myeloproliferative neoplasm-associated pulmonary hypertension","volume":"32","author":"Kim","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jaccao.2025.05.010_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2020.12.023","article-title":"Pulmonary arterial hypertension in hospitalized patients with polycythemia vera (from the National Inpatient Database)","volume":"143","author":"Stempel","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10079","article-title":"Abstract 10079: risk of cardiovascular and all-cause mortality in patients with myeloproliferative neoplasms following heart failure hospitalization","volume":"144","author":"Leiva","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.05.010_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canep.2015.01.014","article-title":"Risk of Wernicke\u2019s encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm","volume":"39","author":"Wu","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.119046","article-title":"Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms","volume":"401","author":"Leiva","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaccao.2025.05.010_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11239-023-02900-z","article-title":"In-hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database","volume":"57","author":"Leiva","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jaccao.2025.05.010_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jjcc.2022.10.007","article-title":"Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation","volume":"81","author":"Leiva","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib26","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib27","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/ehf2.13297","article-title":"Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality","volume":"8","author":"Kiefer","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2025.05.010_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCULATIONAHA.123.064170","article-title":"Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction","volume":"148","author":"Cochran","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2025.05.010_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53244","article-title":"Clonal hematopoiesis and incident heart failure with preserved ejection fraction","volume":"7","author":"Schuermans","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2025.05.010_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.13197","article-title":"Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms","volume":"102","author":"Brabrand","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1080\/10428194.2020.1864351","article-title":"Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension","volume":"62","author":"Khan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2025.05.010_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clml.2020.08.006","article-title":"BCR-ABL1-negative chronic myeloproliferative neoplasms and pulmonary hypertension: a prospective long-term follow-up study of the impact of pulmonary hypertension on survival","volume":"21","author":"Payzin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2025.05.010_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12185-020-02952-4","article-title":"Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients","volume":"112","author":"Jindamai","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5045\/br.2020.2020001","article-title":"Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.jaccao.2025.05.010_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-020-03962-2","article-title":"Prevalence of pulmonary hypertension in myelofibrosis","volume":"99","author":"Lopez-Mattei","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clml.2019.05.009","article-title":"Prevalence and effect on survival of pulmonary hypertension in myelofibrosis","volume":"19","author":"Austin","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2025.05.010_bib37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000506596","article-title":"Association of disease subtype and duration with echocardiographic evidence of pulmonary hypertension in myeloproliferative neoplasm","volume":"29","author":"Yaylali","year":"2020","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.jaccao.2025.05.010_bib38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00277-016-2765-0","article-title":"Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience","volume":"95","author":"Mattar","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.leu.2404943","article-title":"Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status","volume":"22","author":"Cortelezzi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2025.05.010_bib40","first-page":"245","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"89","author":"Garypidou","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2025.05.010_bib41","first-page":"1779","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"98","author":"Gupta","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jaccao.2025.05.010_bib42","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428190701493928","article-title":"Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis","volume":"48","author":"Altintas","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2025.05.010_bib43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13543","article-title":"Prevalence and risk factors for pulmonary hypertension associated with chronic myeloproliferative neoplasms","volume":"106","author":"Ferrari","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1751-7133.2010.00202.x","article-title":"REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension","volume":"17","author":"Farber","year":"2011","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jaccao.2025.05.010_bib45","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2025.05.010_bib46","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.287497","article-title":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms","author":"Leiva","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2025.05.010_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6575","article-title":"Association of elevated pulmonary artery systolic pressure with hematologic progression in myeloproliferative neoplasms","volume":"42","author":"Leiva","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","article-title":"Unexplained pulmonary hypertension in chronic myeloproliferative disorders","volume":"120","author":"Dingli","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2025.05.010_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000112822","article-title":"Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases","volume":"76","author":"Guilpain","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.jaccao.2025.05.010_bib50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical phenotype and outcomes of pulmonary hypertension associated with myeloproliferative neoplasms: a population-based study","volume":"208","author":"Montani","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jaccao.2025.05.010_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11897-020-00476-w","article-title":"Evidence of clonal hematopoiesis and risk of heart failure","volume":"17","author":"Bazeley","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jaccao.2025.05.010_bib54","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2025.05.010_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjcard.2024.06.033","article-title":"Symptomatic heart failure and clonal hematopoiesis-related mutations in patients with acute myeloid leukemia","volume":"226","author":"Kang","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib57","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamacardio.2020.2468","article-title":"Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure","volume":"5","author":"Abplanalp","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2025.05.010_bib59","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jaccao.2025.05.010_bib60","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/ijms21093339","article-title":"Myeloproliferative diseases as possible risk factor for development of chronic thromboembolic pulmonary hypertension\u2014a genetic study","volume":"21","author":"Eichstaedt","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaccao.2025.05.010_bib61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1183\/09031936.00087608","article-title":"Risk factors for chronic thromboembolic pulmonary hypertension","volume":"33","author":"Bonderman","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaccao.2025.05.010_bib62","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1200\/JCO.2005.09.021","article-title":"Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia","volume":"23","author":"Massa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib63","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2353\/ajpath.2008.070705","article-title":"Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension","volume":"172","author":"Asosingh","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib64","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/blood-2010-09-306357","article-title":"Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities","volume":"117","author":"Farha","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3324\/haematol.2014.118463","article-title":"CD133 marks a stem cell population that drives human primary myelofibrosis","volume":"100","author":"Triviai","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2025.05.010_bib66","first-page":"1465","article-title":"Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases","volume":"91","author":"Oppliger Leibundgut","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jaccao.2025.05.010_bib67","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/cells10061338","article-title":"Progenitor\/stem cells in vascular remodeling during pulmonary arterial hypertension","volume":"10","author":"Dierick","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaccao.2025.05.010_bib68","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-03-419275","article-title":"Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension","volume":"120","author":"Asosingh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib69","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1634\/stemcells.2007-0562","article-title":"Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension","volume":"26","author":"Marsboom","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.jaccao.2025.05.010_bib70","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/leu.2017.233","article-title":"The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms","volume":"32","author":"Zhan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2025.05.010_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610217","article-title":"Correlations between the expression of stromal cell activation related biomarkers, L-NGFR, phospho-ERK1-2 and CXCL12, and primary myelofibrosis progression","volume":"28","author":"Szekely","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jaccao.2025.05.010_bib72","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1038\/s41467-021-26435-0","article-title":"Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils","volume":"12","author":"Kimishima","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2025.05.010_bib73","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib74","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib75","first-page":"2660","article-title":"Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study","volume":"109","author":"Bose","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2025.05.010_bib76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-021-01064-8","article-title":"Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice","volume":"14","author":"Minakawa","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2025.05.010_bib77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaccao.2025.05.010_bib78","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib79","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.119.044320","article-title":"Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension","volume":"141","author":"Potus","year":"2020","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.jaccao.2025.05.010_bib80","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/cells12212528","article-title":"The role of clonal hematopoiesis of indeterminant potential and DNA (cytosine-5)-methyltransferase dysregulation in pulmonary arterial hypertension and other cardiovascular diseases","volume":"12","author":"Emon","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jaccao.2025.05.010_bib81","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib82","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3348\/kjr.2014.15.3.376","article-title":"Extramedullary pulmonary hematopoiesis causing pulmonary hypertension and severe tricuspid regurgitation detected by technetium-99m sulfur colloid bone marrow scan and single-photon emission computed tomography\/CT","volume":"15","author":"Ali","year":"2014","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib83","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/2045893217702064","article-title":"Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series","volume":"7","author":"Singh","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jaccao.2025.05.010_bib84","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3109\/10428194.2013.873538","article-title":"Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis","volume":"55","author":"Maccaferri","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2025.05.010_bib85","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3324\/haematol.13203","article-title":"Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation","volume":"93","author":"Chunduri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2025.05.010_bib86","article-title":"Case of pulmonary extramedullary hematopoiesis responding to ruxolitinib","volume":"17","author":"Fujimoto","year":"2022","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.jaccao.2025.05.010_bib87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.10075","article-title":"Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement","volume":"69","author":"Weinschenker","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib88","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2141.2002.03695.x","article-title":"Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia","volume":"118","author":"Steensma","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib89","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.25008","article-title":"The role of extracellular matrix stiffness in megakaryocyte and platelet development and function","volume":"93","author":"Leiva","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib90","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib91","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ajh.27184","article-title":"Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis","volume":"99","author":"Abbonante","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib92","doi-asserted-by":"crossref","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaccao.2025.05.010_bib93","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.4161\/cc.24312","article-title":"Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptide","volume":"12","author":"Eliades","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaccao.2025.05.010_bib94","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood.2019004230","article-title":"Adhesion to fibronectin via alpha5beta1 integrin supports expansion of the megakaryocyte lineage in primary myelofibrosis","volume":"135","author":"Matsuura","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib95","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Lefrancais","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.010_bib97","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137377","article-title":"Lung megakaryocytes are immune modulatory cells","volume":"131","author":"Pariser","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaccao.2025.05.010_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154060","article-title":"Mapping of the lung megakaryocytes: A role in pathogenesis of idiopathic pulmonary arterial hypertension?","volume":"237","author":"Balko","year":"2022","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaccao.2025.05.010_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120602","article-title":"Megakaryocytes in pulmonary diseases","volume":"301","author":"Huang","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.jaccao.2025.05.010_bib100","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1445-5994.1996.tb00642.x","article-title":"Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia","volume":"26","author":"Hill","year":"1996","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib101","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0609.1996.tb01385.x","article-title":"Pulmonary fibrosis with megakaryocyte infiltration in agnogenic myeloid metaplasia with thrombocytosis","volume":"57","author":"Yamauchi","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib102","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice","volume":"110","author":"Leiva","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib103","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood-2015-02-629667","article-title":"Lysyl oxidase is associated with increased thrombosis and platelet reactivity","volume":"127","author":"Matsuura","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib104","first-page":"23","article-title":"Lysyl oxidase inhibition in primary myelofibrosis: a renewed strategy","volume":"1","author":"Piasecki","year":"2020","journal-title":"Arch Stem Cell Ther"},{"key":"10.1016\/j.jaccao.2025.05.010_bib105","doi-asserted-by":"crossref","first-page":"24103","DOI":"10.1074\/jbc.M709897200","article-title":"Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells","volume":"283","author":"Lucero","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaccao.2025.05.010_bib106","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/ATVBAHA.114.303534","article-title":"Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension","volume":"34","author":"Nave","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib107","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1139\/cjpp-2019-0658","article-title":"Endothelin-1 induces lysyl oxidase expression in pulmonary artery smooth muscle cells","volume":"98","author":"Maruyama","year":"2020","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib108","doi-asserted-by":"crossref","first-page":"L423","DOI":"10.1152\/ajplung.00327.2023","article-title":"LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension","volume":"327","author":"Steppan","year":"2024","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib109","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/bloodadvances.2024013970","article-title":"High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera","volume":"9","author":"Gazda","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2025.05.010_bib110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2024-199120","article-title":"Prognostic implications of pulmonary hypertension in myeloproliferative neoplasms and predictors of hematologic progression","volume":"144","author":"Leiva","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib111","first-page":"1628","article-title":"Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor - a pilot study","volume":"17","author":"Kolto","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jaccao.2025.05.010_bib112","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.24656","article-title":"Early detection of pulmonary hypertension in primary myelofibrosis: the role of echocardiography, cardiopulmonary exercise testing, and biomarkers","volume":"92","author":"Sciume","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib113","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.chest.2021.09.007","article-title":"Pulmonary endarterectomy in patients with myeloproliferative neoplasms","volume":"161","author":"Genty","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2025.05.010_bib114","first-page":"443","article-title":"Group 5 pulmonary hypertension: the orphan\u2019s orphan disease","volume":"34","author":"Kalantari","year":"2016","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jaccao.2025.05.010_bib115","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/leu.2014.5","article-title":"Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis","volume":"28","author":"Tabarroki","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2025.05.010_bib116","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2024-207586","article-title":"Incidence, risk factors, and prognostic implications of heart failure hospitalizations among patients with myeloproliferative neoplasms","volume":"144","author":"Leiva","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib117","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40248-016-0082-z","article-title":"Pulmonary arterial hypertension associated with interferon therapy: a population-based study","volume":"12","author":"Papani","year":"2017","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib119","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1183\/09031936.00057914","article-title":"Pulmonary arterial hypertension in patients treated with interferon","volume":"44","author":"Savale","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaccao.2025.05.010_bib120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib121","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib122","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1111\/jcmm.17007","article-title":"PKM2 promotes angiotensin-II-induced cardiac remodelling by activating TGF-\u03b2\/Smad2\/3 and Jak2\/Stat3 pathways through oxidative stress","volume":"25","author":"Zhang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib123","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.117.311045","article-title":"EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-\u03b2\/Smad3 signaling","volume":"121","author":"Su","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2025.05.010_bib124","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2025.05.010_bib125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jaccao.2020.02.018","article-title":"Effect of JAK1\/2 inhibition on High-Output Heart Failure Associated With Myeloproliferative Disease","volume":"2","author":"Fujii","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib126","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib127","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib128","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.010_bib129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.jaccao.2025.05.010_bib130","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/biomedicines11051301","article-title":"Polypharmacy, potentially inappropriate medications, and drug-to-drug interactions in patients with chronic myeloproliferative neoplasms","volume":"11","author":"Krecak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaccao.2025.05.010_bib131","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-11-752600","article-title":"ACE inhibitors and cytoreductive therapy in polycythemia vera","volume":"129","author":"Barbui","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib132","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1111\/jcmm.13710","article-title":"Captopril mitigates splenomegaly and myelofibrosis in the murine model of myelofibrosis","volume":"22","author":"Corey","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib133","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1002\/ajh.27048","article-title":"Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: impact on hemoglobin\/hematocrit levels and outcomes among 11 consecutive patients","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib134","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179596","article-title":"Sodium-glucose co-transporter-2 inhibitor use in the setting of myeloproliferative neoplasms: impact on hemoglobin\/hematocrit levels and thrombosis risk","volume":"142","author":"Gangat","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2025.05.010_bib135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ajh.23881","article-title":"Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?","volume":"90","author":"Vianello","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2025.05.010_bib137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2019.08.004","article-title":"Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients","volume":"68","author":"Venton","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaccao.2025.05.010_bib138","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10428194.2013.797083","article-title":"Pulmonary hypertension in patients with chronic myeloproliferative neoplasms","volume":"55","author":"Chebrek","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325002376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T01:31:53Z","timestamp":1755653513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325002376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666087325002376"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.010","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}